Working… Menu

Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03340376
Recruitment Status : Recruiting
First Posted : November 13, 2017
Last Update Posted : May 22, 2018
Roche Pharma AG
Information provided by (Responsible Party):
Universitaire Ziekenhuizen Leuven

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : July 2019
Estimated Study Completion Date : July 2020